Synthetic Biologics (SYN) Tops Q3 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
November 8, 2018 4:10 PM ESTROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ --Â Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three and nine months ended September 30, 2018.
... More